Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 2/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | FPR2 | P25090 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ESRRB | O95718 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESRRA | P11474 | 1/20 | 0.41 |
| ▸ | ESRRG | P62508 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23906274 | 0.92 | ESR2 (0.47) | GRM5RORCESR2SMN1; SMN2NPC1 | |
| SCHEMBL1870570 | 0.86 | NR1H2 (0.54) | GRM5ESR2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL4635083 | 0.86 | GRM5 (0.46) | GRM5RORCESR2SMN1; SMN2NR1H2 | |
| SCHEMBL5497099 | 0.86 | MEN1 (0.55) | GRM5ESR2SMN1; SMN2NR1H2LMNA | |
| SCHEMBL1473227 | 0.86 | GPR119 (0.51) | GRM5ESR2NR1H2GPR119 | |
| SCHEMBL17542019 | 0.86 | HDAC1 (0.48) | RORCESR2SMN1; SMN2NPC1RECQL | |
| SCHEMBL14720589 | 0.86 | GRM5 (0.43) | GRM5ESR2SMN1; SMN2NR1H2USP2 | |
| SCHEMBL20304919 | 0.85 | SRD5A2 (0.55) | GRM5ESR2NR1H2GPR119MEN1 | |
| SCHEMBL15699606 | 0.85 | ALDH1A1 (0.54) | GRM5SMN1; SMN2LMNAGPR119ALDH1A1 | |
| SCHEMBL1363915 | 0.85 | GRM5 (0.47) | GRM5RORCESR2NR1H2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441702-B2 | Substituted 4-benzyl and 4-benzoyl piperidine derivates | CEPHALON LLC (US) | 2025-10-14 | — | — | US | disclosed |
| US-20240166625-A1 | Substituted 4-Benzyl And 4-Benzoyl Piperidine Derivates | CEPHALON LLC | 2024-05-23 | — | — | US | disclosed |
| US-11878966-B2 | Substituted 4-benzyl and 4-benzoyl piperidine derivates | 89BIO LTD (IL) | 2024-01-23 | — | — | US | disclosed |
| US-20220081411-A1 | Substituted 4-Benzyl And 4-Benzoyl Piperidine Derivates | CEPHALON LLC | 2022-03-17 | — | — | US | disclosed |
| US-10919875-B2 | Substituted 4-benzyl and 4-benzoyl piperidine derivatives | 89BIO LTD (IL) | 2021-02-16 | — | — | US | disclosed |
| EP-3310773-B1 | SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES | 89BIO LTD (IL) | 2020-12-02 | — | — | EP | disclosed |
| US-20200031797-A1 | SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES | CEPHALON LLC | 2020-01-30 | — | — | US | disclosed |
| EP-3310773-A1 | SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES | Cephalon, Inc. (US) | 2018-04-25 | — | — | EP | disclosed |
| WO-2016205590-A1 | SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES | CEPHALON, INC. (US) | 2016-12-22 | — | — | WO | disclosed |
| WO-2013027001-A1 | COMPOUNDS AND THEIR USE TO TREAT HISTAMINE H3 RELATED DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | WO | disclosed |
| WO-2013027001-A1 | COMPOUNDS AND THEIR USE TO TREAT HISTAMINE H3 RELATED DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12441702-B2 | Substituted 4-benzyl and 4-benzoyl piperidine derivates | FASN, CES1, FADS2 | GRM5 2554/4885RORC 2728/4885ESR2 3057/4885 |
| US-20240166625-A1 | Substituted 4-Benzyl And 4-Benzoyl Piperidine Derivates | FASN, CES1, FADS2 | GRM5 2554/4885RORC 2728/4885ESR2 3057/4885 |
| US-20200031797-A1 | SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES | FASN, FADS1, ASS1 | GRM5 2450/4885RORC 3034/4885ESR2 2352/4885 |
| US-10919875-B2 | Substituted 4-benzyl and 4-benzoyl piperidine derivatives | FASN, CES1, FADS2 | GRM5 2861/4885RORC 2851/4885ESR2 3118/4885 |
| US-20220081411-A1 | Substituted 4-Benzyl And 4-Benzoyl Piperidine Derivates | FASN, CES1, FADS2 | GRM5 2554/4885RORC 2728/4885ESR2 3057/4885 |
| US-11878966-B2 | Substituted 4-benzyl and 4-benzoyl piperidine derivates | FASN, CES1, FADS2 | GRM5 2554/4885RORC 2728/4885ESR2 3057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.